ArticleSubstance abuse2015
Cost-Effectiveness of Injectable Extended-Release Naltrexone Compared With Methadone Maintenance and Buprenorphine Maintenance Treatment for Opioid Dependence.
Article in Substance abuse, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 5 syntheses or guidelines pooled it, 54 citations in OpenAlex.
- Cost per Opioid-Free Year: A Systematic Review and Summary Analysis.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2025Pooled it
- A Systematic Review of Simulation Models to Track and Address the Opioid Crisis.Epidemiologic reviews · 2022Pooled it
- Economic Evaluation in Opioid Modeling: Systematic Review.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2021Pooled it
- Economic Evaluations of Opioid Use Disorder Interventions.PharmacoEconomics · 2016Pooled it
- A systematic review of modelling approaches in economic evaluations of health interventions for drug and alcohol problems.BMC health services research · 2016Pooled it
- Health care use and cost of treatment for adolescents and young adults with opioid use disorder.Journal of substance use and addiction treatment · 2023Trial
- Cost-effectiveness of extended release naltrexone to prevent relapse among criminal justice-involved individuals with a history of opioid use disorder.Addiction (Abingdon, England) · 2017Trial
- Ibogaine for Substance Use Disorders.Advances in therapy · 2026Review
- Informing evidence-based medicine for opioid use disorder using pharmacoeconomic studies.Expert review of pharmacoeconomics & outcomes research · 2024Review
- Targeting Opioid Receptors in Addiction and Drug Withdrawal: Where Are We Going?International journal of molecular sciences · 2023Review
- Cost-effectiveness of scaling-up HCV prevention and treatment in the United States for people who inject drugs.Addiction (Abingdon, England) · 2019Article
- Treating opioid dependence with extended-release naltrexone (XR-NTX) in Ukraine: Feasibility and three-month outcomes.Journal of substance abuse treatment · 2019Article
- Medicaid Benefits For Addiction Treatment Expanded After Implementation Of The Affordable Care Act.Health affairs (Project Hope) · 2018Article
- Cost of provision of opioid substitution therapy provision in Tijuana, Mexico.Harm reduction journal · 2018Article
- Scaling-up HCV prevention and treatment interventions in rural United States-model projections for tackling an increasing epidemic.Addiction (Abingdon, England) · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
backgroundThe aim of this study was to estimate the cost-effectiveness of injectable extended-release naltrexone (XR-NTX) compared with methadone maintenance and buprenorphine maintenance treatment (MMT and BMT, respectively) for adult males enrolled in treatment for opioid dependence in the United States from the perspective of state-level addiction treatment payers.
methodsA Markov model with daily time cycles was used to estimate the incremental cost per opioid-free day in a simulated cohort of adult males aged 18-65 over a 6-month period from the state health program perspective.
resultsXR-NTX is predicted to be more effective and more costly than methadone or buprenorphine in our target population, with an incremental cost per opioid-free day gained relative to the next-most effective treatment (MMT) of $72. The cost-effectiveness of XR-NTX relative to MMT was driven by its effectiveness in deterring opioid use while receiving treatment.
conclusionsXR-NTX is a cost-effective medication for treating opioid dependence if state addiction treatment payers are willing to pay at least $72 per opioid-free day.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.